Otolith Labs
Otolith Labs is pioneering non-invasive wearable medical devices for the treatment of vestibular disorders, especially chronic vertigo. Their patented technology utilizes non-invasive Vestibular Resonance Therapy (nVRT) to impact the vestibular system, providing immediate relief for vertigo symptoms. The company is committed to solving vertigo through innovative, safe, and effective solutions, validated by clinical studies and recognized by FDA Breakthrough Device designation.
Industries
Nr. of Employees
small (1-50)
Otolith Labs
Products
Investigational head-worn vestibular stimulation device (wearable)
An investigational headband wearable that delivers calibrated mechanical vibrations (bone-conducted) to interact with inner-ear acceleration sensors for treatment or acute relief of vertigo symptoms; currently used in clinical trials and research studies.
Investigational head-worn vestibular stimulation device (wearable)
An investigational headband wearable that delivers calibrated mechanical vibrations (bone-conducted) to interact with inner-ear acceleration sensors for treatment or acute relief of vertigo symptoms; currently used in clinical trials and research studies.
Services
Recruitment and coordination of on-site clinical studies for vestibular disorders, including participant screening, site engagement and study logistics.
Partnerships with universities and independent investigators to conduct exploratory and controlled research studies, enabling external validation and peer-reviewed outputs.
Recruitment and coordination of on-site clinical studies for vestibular disorders, including participant screening, site engagement and study logistics.
Partnerships with universities and independent investigators to conduct exploratory and controlled research studies, enabling external validation and peer-reviewed outputs.
Expertise Areas
- Clinical trial management for medical devices
- Vestibular therapy device development
- Wearable medical device engineering
- Regulatory strategy for novel devices (FDA Breakthrough, De Novo)
Key Technologies
- Head-worn wearable medical devices
- Bone-conducted vibration delivery
- Vestibular stimulation via calibrated mechanical vibrations
- Precision waveform generation and embedded signal control
News & Updates
Kevin Franck, PhD, MBA appointed as Otolith Labs’ Chief Clinical Officer.
Otolith appointed Dan Wagner as Chief Commercial Officer and Raphael Michel to Otolith’s Board of Directors.
Otolith Labs raised $20 million in Series A financing, with CEO Sam Owen discussing the company's progress.
Otolith Labs announced the FDA Breakthrough Device designation for its non-invasive treatment device for vertigo.
Research published by Frontiers demonstrating Otolith's technology reduces cybersickness in virtual reality.
Otolith Labs was one of the three winning teams in NASA’s iTech initiative in 2020.
Kevin Franck, PhD, MBA appointed as Otolith Labs’ Chief Clinical Officer.
Otolith appointed Dan Wagner as Chief Commercial Officer and Raphael Michel to Otolith’s Board of Directors.
Otolith Labs raised $20 million in Series A financing, with CEO Sam Owen discussing the company's progress.
Otolith Labs announced the FDA Breakthrough Device designation for its non-invasive treatment device for vertigo.
Research published by Frontiers demonstrating Otolith's technology reduces cybersickness in virtual reality.
Otolith Labs was one of the three winning teams in NASA’s iTech initiative in 2020.